← Back to Search

e-Intervention for Alcohol Use in Pregnancy (e-Health Trial)

N/A
Recruiting
Led By Steven J Ondersma, PhD
Research Sponsored by Michigan State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18-35 years
Be between 18 and 65 years old
Must not have
Unable to communicate in English
Timeline
Screening 3 weeks
Treatment Varies
Follow Up entire period of gestation

Summary

This trial is testing a new alcohol intervention for pregnant women, to see if it reduces alcohol use and if booster sessions or text messages can help.

Who is the study for?
This trial is for pregnant women aged 18-35, less than 20 weeks along, living in Connecticut, Massachusetts, or Michigan. They must own a mobile device and have reported alcohol use that poses a risk to fetal health. Women not intending to carry the pregnancy to term or unable to communicate in English cannot participate.
What is being tested?
The study tests an app called MommyCheckup designed for pregnant women at risk of alcohol-related issues. It delivers brief interventions and checks if additional booster sessions or personalized text messages can further reduce alcohol consumption during pregnancy.
What are the potential side effects?
Since this trial involves non-medical interventions like apps and text messaging, there are no direct medical side effects. However, participants may experience stress or discomfort when discussing their alcohol use.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 35 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot communicate in English.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants abstinent from alcohol as measured by Timeline FollowBack Calendar Recall and Ethyl Glucuronide (EtG)
Secondary study objectives
Number of participants with a healthy birth outcome (full-term live birth of normal birthweight, with no days in NICU)

Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: General information + SMSExperimental Treatment2 Interventions
SMS refers to tailored text messaging.
Group II: Baseline brief intervention + SMSExperimental Treatment2 Interventions
Brief technology-delivered intervention for alcohol use during pregnancy, plus tailored text messaging
Group III: Baseline brief intervention + 2 booster sessions + SMSExperimental Treatment3 Interventions
Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (\<5 minutes) online boosters using the participants' own mobile device, plus tailored SMS.
Group IV: Baseline brief intervention + 2 booster sessionsExperimental Treatment2 Interventions
Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (\<5 minutes) online boosters using the participants' own mobile device.
Group V: Baseline brief interventionExperimental Treatment1 Intervention
Brief technology-delivered intervention for alcohol use during pregnancy
Group VI: General informationPlacebo Group1 Intervention
Control
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SMS
2016
N/A
~62160

Find a Location

Who is running the clinical trial?

Michigan State UniversityLead Sponsor
198 Previous Clinical Trials
684,856 Total Patients Enrolled
National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
836 Previous Clinical Trials
1,082,546 Total Patients Enrolled
15 Trials studying Fetal Alcohol Spectrum Disorders
3,349 Patients Enrolled for Fetal Alcohol Spectrum Disorders
University of Massachusetts, WorcesterOTHER
362 Previous Clinical Trials
992,662 Total Patients Enrolled

Media Library

Baseline brief intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT04332172 — N/A
~128 spots leftby Aug 2025